Ambac Financial Earnings Call Highlights Turnaround Momentum

Ambac Financial Group ((OSG)) has held its Q1 earnings call. Read on for the main highlights of the call.

Ambac Financial Group’s latest earnings call struck a notably upbeat tone, as management highlighted strong operational momentum despite headline GAAP losses. Executives focused on sharp gains in Insurance Distribution, improving non‑GAAP profitability, tighter cost control and early benefits from their platform and AI strategy, while carefully isolating one‑off legal and startup-related drags that obscured underlying progress.

Insurance Distribution Revenue Surge

Insurance Distribution led the quarter, with total revenues soaring 92% year over year to $78.5 million. Management credited a powerful mix of 42% organic growth and the October 2025 acquisition of ArmadaCare, positioning the segment as the core earnings engine and underscoring the scalability of the MGA-focused model.

Insurance Distribution Profitability Expansion

Profitability in Insurance Distribution improved even faster than revenue, as adjusted EBITDA nearly quadrupled to about $25 million. Segment margins expanded sharply to roughly 32% from 17% a year earlier, highlighting operating leverage as scale builds and integration benefits from ArmadaCare and other MGAs begin to flow through.

Material Improvement in Consolidated Non-GAAP Earnings

On a consolidated basis, Ambac’s non‑GAAP metrics showed a dramatic turnaround, with adjusted EBITDA to shareholders rising to $20.1 million from a loss of $1.3 million. Adjusted net income swung to $16.6 million, or $0.37 per share, compared with a $6.0 million loss a year earlier, signaling that the company’s transformation efforts are beginning to translate into tangible earnings power.

Narrowing of GAAP Net Loss

While still in the red on a GAAP basis, Ambac significantly narrowed its net loss to shareholders to $6.9 million, or $0.13 per share, from $16.1 million, or $0.57 per share, a year earlier. Management emphasized that this 57% improvement comes even after absorbing sizeable one-time charges, suggesting further upside as non‑recurring items roll off.

Everspan Premium Growth and Loss-Ratio Improvement

Everspan, Ambac’s specialty carrier platform, posted solid top-line momentum, with gross premiums written up 19% to $104 million and net premiums written rising 80% to $32 million. Earned premiums climbed 28% to $20 million, while the accident year loss ratio improved to 54% overall, with active programs near 57%, indicating better underwriting discipline and portfolio reshaping.

Corporate Expense Reduction Progress

Cost discipline was another bright spot, as reported corporate expenses fell to just over $12 million from $15 million year over year. On an adjusted basis, corporate costs dropped to $7.2 million from $10.6 million, reflecting targeted restructuring and efficiency initiatives that are helping to support margin expansion across the platform.

Balance Sheet, Capacity and Financing

Ambac’s Insurance Distribution unit ended the quarter with pro forma net debt-to-EBITDA of about 3.2 times on a trailing basis, a level management views as manageable for a growing platform. The company secured five-year bank facilities with spreads initially at 275 basis points over SOFR, and increased third-party capacity from $1.5 billion to over $2 billion, expanding its ability to support MGA growth.

Strategic M&A and Capital Deployment

Capital deployment remained active, with Ambac completing buy-ins that lifted its stake in Octave Ventures by 10% and adding interests in four other MGAs for roughly $44 million, funded through cash and an expanded term loan. ArmadaCare also continued to perform, delivering about 10% organic revenue growth versus its prior-year quarter, validating the strategic rationale for the deal.

Platform and AI Strategy

Management reiterated a clear vision to build a scalable MGA platform supported by a unified technology stack and robust AI capabilities. The company is pursuing a two-track AI approach, combining proprietary tools with curated partners, and has selected Anthropic as a core AI solution, aiming to standardize MGAs on a homogeneous stack to unlock data-driven pricing, underwriting and productivity gains.

Strong Q1 Seasonality and Positive Outlook

Executives described Q1 as a strong seasonal quarter that came in ahead of plan, with particular strength in accident and health lines. While guidance remains unchanged for now, they signaled potential upside later in the year and expect to launch one or two new MGAs in 2026, underscoring a disciplined approach to growth rather than chasing volume at any cost.

Reported GAAP Headline Loss and Everspan Pre-Tax Loss

Despite the underlying improvements, the company still reported a GAAP net loss to shareholders of $6.9 million for the quarter. Everspan also posted a pre-tax loss of $8 million, reminding investors that the transformation is ongoing and that certain lines and programs continue to weigh on reported results even as pro forma economics trend better.

Large One-Time Litigation and Settlement Impact

A major litigation settlement tied to a potential insurance claim weighed heavily on the quarter, adding $2.1 million of losses and $5.8 million of legal expenses. Management noted that this settlement alone contributed roughly 39.6 percentage points to the loss ratio, significantly inflating the reported loss adjustment expense ratio to 98.4% for the period.

Distorted Combined and LAE Ratios from One-Offs

Reported combined and loss adjustment expense ratios were heavily distorted by the settlement, severance and other timing items, making headline ratios less indicative of ongoing performance. On a pro forma basis, management pointed to a combined ratio near 95%, which they believe better reflects the underlying trend and aligns with long-term underwriting targets.

De Novo MGA Cost Drag and Early-Stage Losses

Ambac noted that roughly 40% of its MGAs, or nine programs, are de novo launches from 2024 and 2025, many of which are still loss-making on an adjusted EBITDA basis. These early-stage investments reduced EBITDA by about $1.1 million in Q1, versus $0.6 million a year earlier, as the company continues to prioritize building future growth pillars over near-term earnings.

Ongoing Non-Recurring and Compensation Charges

The quarter also included several non-recurring and compensation-related items, including about $1.1 million of acquisition and integration costs and $0.5 million of severance and restructuring charges. Equity-based compensation totaled $3.1 million, including a $1.7 million catch-up accrual, which management excludes from adjusted metrics but which still depresses GAAP earnings.

Everspan Reported LAE Volatility

While Everspan’s accident year loss ratios showed improvement, its reported net loss adjustment expense ratio spiked to 98.4% due to the litigation-related legal and settlement costs. This highlighted the volatility inherent in certain lines and programs, and management emphasized ongoing efforts to refine underwriting, reshape portfolios and reduce exposure to problematic risks.

Leverage and Collateral Considerations

With Insurance Distribution debt-to-EBITDA around 3.2 times, leverage is meaningful but, in management’s view, appropriate for a capital-light fee-based model. The company has also provided equity in Everspan’s intermediate holding company as additional collateral for bank-funded insurance financing, which enhances lender confidence but adds another layer of structural complexity.

Quarter-to-Quarter Variability and Seasonality

Management cautioned that investors should expect quarter-to-quarter variability driven by seasonality and the timing of new MGA launches, with Q1 typically the strongest and Q4 the second strongest. De novo programs can depress earnings in the short term, but executives argue that improving underlying metrics and growing fee income help offset this noise over a full year.

Forward-Looking Guidance and Outlook

Ambac reiterated that its 2026 guidance remains essentially unchanged from its February outlook, even after Q1 outperformance, with organic growth expected to be the primary driver and accident and health business targeted at around 30% of production. Management plans one to two de novo MGA launches this year, has no further minority buy-ins planned after spending about $44 million this quarter, and sees Everspan’s improving pro forma combined ratio near 95% as evidence that its repositioning is on track.

The call painted a picture of a company in transition but gaining traction, with Insurance Distribution delivering outsized growth and margins while Everspan and corporate actions still weigh on GAAP results. For investors, the key takeaway is that Ambac’s non‑GAAP profitability and platform strategy are moving in the right direction, though continued execution and taming of one-off volatility will be crucial for the story to fully re-rate.